Ceclazepide is under clinical development by Trio Medicines and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ceclazepide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ceclazepide overview

Ceclazepide (TR-2A) is under development for the treatment of gastro-oesophageal reflux disease, pancreatic cancer, gastric cancer, Barett's oesophagus, and helicobacter pylori Infections. It acts by targeting gastrin/CCK2. It was also under development for gastric neuroendocrine tumors (US and EU).

Trio Medicines overview

Trio Medicines operates in pharmaceutical and healthcare industry. It operates as a subsidiary of Hammersmith Medicines Research Ltd and is headquartered in United Kingdom.

For a complete picture of Ceclazepide’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.